HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francesca Guerrini Selected Research

Lymphoproliferative Disorders (Lymphoproliferative Disorder)

8/2007Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francesca Guerrini Research Topics

Disease

8BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2020 - 10/2005
5Residual Neoplasm
05/2022 - 09/2004
5Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/2020 - 06/2010
3Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2019 - 01/2017
2Carcinogenesis
06/2020 - 06/2010
2Lymphoma (Lymphomas)
01/2019 - 01/2018
2Hematologic Neoplasms (Hematological Malignancy)
01/2018 - 10/2005
2Multiple Myeloma
12/2017 - 08/2005
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
09/2012 - 12/2009
1Pdgfra-Associated Chronic Eosinophilic Leukemia
09/2020
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2020
1Infections
01/2020
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2019
1Waldenstrom Macroglobulinemia (Macroglobulinemia)
01/2018
1Monoclonal Gammopathy of Undetermined Significance
01/2018
1Hypoxia (Hypoxemia)
06/2010
1Leukemia
06/2010
1Myeloproliferative Disorders (Myeloproliferative Disorder)
06/2010
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
08/2007
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
08/2007
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
09/2004
1Fever (Fevers)
09/2004

Drug/Important Bio-Agent (IBA)

4Tyrosine Kinase InhibitorsIBA
01/2020 - 08/2015
4Imatinib Mesylate (Gleevec)FDA Link
10/2017 - 10/2005
2nilotinibFDA Link
01/2020 - 10/2017
2Cell-Free Nucleic AcidsIBA
01/2019 - 01/2018
2Arsenic Trioxide (Trisenox)FDA Link
09/2012 - 06/2010
1Sorafenib (BAY 43-9006)FDA Link
09/2020
1Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
06/2020
1enasidenibIBA
06/2020
1Antiviral Agents (Antivirals)IBA
01/2020
1Immunoglobulin M (IgM)IBA
01/2018
1Immunoglobulin G (IgG)IBA
01/2018
1Proteins (Proteins, Gene)FDA Link
01/2018
1Protein Isoforms (Isoforms)IBA
12/2017
1Rituximab (Mabthera)FDA Link
01/2017
1Bendamustine HydrochlorideFDA Link
01/2017
1Ascorbic Acid (Vitamin C)FDA LinkGeneric
09/2012
1givinostat hydrochlorideIBA
11/2010
1Histone Deacetylase InhibitorsIBA
11/2010
1Epidermal Growth Factor (EGF)IBA
06/2010
1Bortezomib (Velcade)FDA Link
06/2010
1CytokinesIBA
06/2010
1Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA
12/2009
1Glutathione (Reduced Glutathione)IBA
08/2007
1Alemtuzumab (Campath)FDA Link
09/2004

Therapy/Procedure

3Therapeutics
05/2022 - 09/2004
1Transplantation
01/2019
1Immunotherapy
01/2019
1Homologous Transplantation
08/2005
1Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
08/2005
1Subcutaneous Injections
09/2004